Supply Chain Optimization and Decentralized Manufacturing to Expand the Contract Cell and Gene Therapy Manufacturing Market, 2020–2026
Automation Deployed to Contain Cost of Goods Sold and Vector Manufacturing Standardization will Create New Growth Opportunities
  • The cell and gene therapy segment is one of the fastest growing segments in the biopharmaceutical space. While the science behind the therapy has grown by leaps and bounds on the back of decades worth of research, manufacturing has unfortunately lagged behind. To fully harness the curative potential of these therapies and ensure greater reach and affordability to patients, it is imperative that aggressive investments in manufacturing technology and capacity are made today. Investments in manufacturing technology advancements including automation, single-use technologies, and GMP-in-a-box, will not only enable operational efficiency gains but also reduce project costs, generating benefits which can be transferred directly to the patients.

    • Access Preview
    • * indicates mandatory fields
    • Full Name*
    • Company*
    • Business Phone*
    • Business Email*
    • Country*
    • Job Role*
    • Are you in the media?*
    • To Manage Your Communication Preferences, Click Here.
    • Frost & Sullivan values your privacy and we will never share or sell your personal information to third parties. Please visit our Privacy Policy.